Previous close | 1.0200 |
Open | 1.0200 |
Bid | 0.1500 |
Ask | 1.4000 |
Strike | 26.00 |
Expiry date | 2024-06-21 |
Day's range | 1.0200 - 1.0200 |
Contract range | N/A |
Volume | |
Open interest | 100 |
Key Insights Revolution Medicines will host its Annual General Meeting on 20th of June Total pay for CEO Mark Goldsmith...
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. Details of the company’s participation are as follows: Goldman Sachs 45th Annual Gl
Insights into RVMD's Financial Health and Future Directions